Hims & Hers Health (NYSE:HIMS) CFO Sells $956,279.80 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 36,922 shares of the company’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $25.90, for a total value of $956,279.80. Following the sale, the chief financial officer owned 281,867 shares of the company’s stock, valued at $7,300,355.30. The trade was a 11.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, April 20th, Oluyemi Okupe sold 19,645 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.96, for a total value of $588,564.20.
• On Friday, April 17th, Oluyemi Okupe sold 18,005 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.83, for a total value of $501,079.15.
• On Monday, April 6th, Oluyemi Okupe sold 3,975 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.98, for a total value of $79,420.50.
• On Friday, March 20th, Oluyemi Okupe sold 9,217 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.77, for a total value of $219,088.09.
• On Tuesday, January 20th, Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.34, for a total value of $275,092.78.

Hims & Hers Health Stock Down 2.7%

NYSE HIMS opened at $28.95 on Thursday. The business has a fifty day moving average price of $20.45 and a two-hundred day moving average price of $31.74. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The stock has a market capitalization of $6.60 billion, a PE ratio of 56.77, a PEG ratio of 2.83 and a beta of 2.32.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm had revenue of $617.82 million during the quarter, compared to analysts’ expectations of $619.48 million. During the same period in the prior year, the company earned $0.11 earnings per share. The company’s quarterly revenue was up 28.4% on a year-over-year basis. Equities analysts expect that Hims & Hers Health, Inc. will post 0.61 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on HIMS shares. Deutsche Bank Aktiengesellschaft upped their price target on shares of Hims & Hers Health from $25.00 to $28.00 and gave the stock a “hold” rating in a report on Tuesday, March 10th. Needham & Company LLC upgraded shares of Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a report on Monday, March 9th. Morgan Stanley lowered their price target on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Leerink Partners increased their price objective on Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a report on Monday, March 16th. Finally, Evercore set a $24.00 price objective on Hims & Hers Health in a report on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and an average price target of $31.86.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Pipeline & partner speculation — Momentum behind HIMS has been driven by reports of FDA peptide news and a potential partnership with Novo Nordisk, which traders say helped push the stock higher as investors price in new commercial opportunities. Read More.
• Positive Sentiment: Product expansion — HIMS announced it will offer perimenopause/menopause treatment options (including estrogen patch access) on its telehealth platform, expanding addressable market and recurring-care use cases. This is a direct revenue opportunity and supports the company’s DTC care‑platform narrative. Read More.
• Neutral Sentiment: Sector/flow dynamics — Broader small‑cap biotech and telehealth sector enthusiasm (positive clinical results at peers, flow into health names) has amplified HIMS moves even where company‑specific catalysts are limited. That can accelerate swings up or down ahead of earnings. Read More.
• Neutral Sentiment: Analyst & institutional backdrop — Coverage is mixed: consensus is a “Hold” with a mid‑$30s/low‑$20s range of targets and heavy institutional ownership (~63%). Upgrades/target changes have helped sentiment but don’t fully resolve execution risk.
• Negative Sentiment: Insider selling — CFO Oluyemi Okupe and other insiders have sold sizable blocks recently under pre‑arranged Rule 10b5‑1 plans (April filings). While 10b5‑1 execution mutes signaling, the volume and timing can weigh on near‑term sentiment. Read More. Read More.
• Negative Sentiment: Competitive threat — Amazon’s launch of a GLP‑1 weight‑loss program highlights new, deep-pocketed competition in a key monetizable category for HIMS (weight‑loss/medication access + ongoing care). That announcement pressured the stock amid concerns about margin compression and customer share loss. Read More.

Institutional Trading of Hims & Hers Health

A number of institutional investors have recently bought and sold shares of HIMS. Quent Capital LLC bought a new stake in Hims & Hers Health during the third quarter valued at $28,000. Flagship Harbor Advisors LLC bought a new position in shares of Hims & Hers Health during the 4th quarter worth about $28,000. Binnacle Investments Inc bought a new position in shares of Hims & Hers Health during the 3rd quarter worth about $28,000. Bogart Wealth LLC boosted its position in shares of Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares in the last quarter. Finally, Geneos Wealth Management Inc. bought a new position in shares of Hims & Hers Health during the 1st quarter worth about $30,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.